Empagliflozin
- PDF / 169,376 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 58 Downloads / 189 Views
1 S
Euglycaemic diabetic ketoacidosis: case report A 56-year-old man developed euglycaemic diabetic ketoacidosis while receiving empagliflozin for type II diabetes mellitus (DM). The man, who had type II DM and hypothyroidism, presented with nausea and vomiting for few days. Recently, he was prescribed oral empagliflozin [dosage not stated] as an adjunct to metformin to control his diabetes. At the time of admission, investigations were as follows: glucose 246 mg/dl, PH 7.03, anion gap 24, HCO3 6 mEq/L, serum Beta hydroxybutyrate more than 8 mg/dL and lactic acid 4.9 mg/dL. He was diagnosed with euglycaemic diabetic ketoacidosis [duration of treatment to reaction onset not stated]. The man was successfully treated with IV insulin infusion, unspecified IV fluids and withdrawal of all oral antidiabetic agents. Afterwards, he was discharged on metformin and insulin therapy. Khaliq MF, et al. Euglycemic diabetic ketoacidosis secondary to sodium-glucose cotransporter 2 inhibitors. American Journal of Respiratory and Critical Care Medicine 199: 803447365 abstr. A1728, No. 9, May 2019. Available from: URL: https://doi.org/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1728 [abstract]
0114-9954/20/1787-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 18 Jan 2020 No. 1787
Data Loading...
